← Back to Search

READyR II: A for Alzheimer's Disease (READyR-II Trial)

N/A
Waitlist Available
Led By Lyndsey M Miller, PhD
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up continuously over 18 weeks
Awards & highlights

READyR-II Trial Summary

This trial is testing whether a remote assessment can help adapt care for people with dementia based on their changing needs.

Eligible Conditions
  • Alzheimer's Disease
  • Dementia
  • Marital Relationships
  • Caregiver Stress Syndrome

READyR-II Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~continuously over 18 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and continuously over 18 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean difference effect sizes for pre-post change in the amount of incongruence between the care partner's understanding of the care values of the person with dementia
Mean difference effect sizes for pre-post change in the care dyad's relationship quality
Mean difference effect sizes for pre-post change the care dyad's preparation for future care needs
Secondary outcome measures
Mean difference effect sizes for pre-post change in the amount of care-related strain reported
Mean difference effect sizes for pre-post change in the care dyad's concealment of emotions
Mean difference effect sizes for pre-post change in the care dyad's quality of life
Other outcome measures
Physical activity / sedentary behavior
Sleep patterns
Time spent out of the home
+1 more

READyR-II Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: READyR II AExperimental Treatment1 Intervention
Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.
Group II: READyR II B (comparison)Active Control1 Intervention
Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
READyR II: A
2021
N/A
~30

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
973 Previous Clinical Trials
7,385,782 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,672 Previous Clinical Trials
28,018,633 Total Patients Enrolled
Lyndsey M Miller, PhDPrincipal InvestigatorOregon Health and Science University
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
REmote Assessment and Dynamic Response Intervention II
Lyndsey Miller 2021. "REmote Assessment and Dynamic Response Intervention II". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04686838.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top